Superstat

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Superstat

Property Description
Active ingredient Rosuvastatin calcium
Form Film-coated tablet
Pharmacological class HMG-CoA reductase inhibitor (Statin)
Common use Management of high blood lipids (dyslipidemia)
Origin Fully synthetic

Superstat is a prescription-only medicine that utilizes Rosuvastatin calcium as its sole active constituent. The medication is classified as a high-potency statin, belonging to the pharmacological class known as HMG-CoA reductase inhibitors. Rosuvastatin is a fully synthetic chemical entity and is clinically recognized for its efficacy in modulating lipid profiles compared to older compounds within its class.

Composition and Physical Form

As a single active ingredient product, the primary component providing the therapeutic effect is Rosuvastatin calcium. This substance is prepared for oral administration, typically formulated as a durable, film-coated tablet. The common tablet form is standard for statins, ensuring reliable drug delivery via the gastrointestinal tract. Unlike liquid or injectable preparations, the film coating aids in facilitating smooth ingestion.

General Purpose and Benefit

The general purpose of Superstat is the proactive management of elevated levels of cholesterol and other circulating fats in the blood, a condition medically termed dyslipidemia. Its core benefit stems from its targeted action in the liver, where it competitively blocks the HMG-CoA reductase enzyme, a necessary step in cholesterol synthesis. By promoting the reduction of cholesterol synthesis, the drug enhances the liver's capacity to clear harmful Low-Density Lipoprotein Cholesterol (LDL-C) from the bloodstream, thereby helping to normalize fat levels.

Regulatory References

  1. NIH/NCBI Statins

What side effects are possible with Superstat?

Possible Side Effects and Safety Information

The safety profile of Superstat (rosuvastatin calcium) is established in official regulatory documents, classifying potential adverse reactions by frequency and physiological system. This information is purely descriptive, detailing the risk profile as documented by health authorities.


Frequency-Classified Adverse Reactions

Adverse reactions are grouped according to how often they have been observed in clinical data:

  • Common (may affect up to 1 in 10 people): Headache, Myalgia (muscle pain), Asthenia (weakness), Constipation, Nausea, Abdominal pain, and Dizziness. New-onset Diabetes Mellitus is also classified as common.
  • Uncommon (may affect up to 1 in 100 people): Pruritus (itching), Rash, and Urticaria (hives).
  • Rare (may affect up to 1 in 1,000 people): Myopathy (muscle disease), Rhabdomyolysis (severe muscle breakdown), Pancreatitis, and Hypersensitivity reactions such as angioedema. Elevations in liver enzymes (Hepatic transaminases) are also rare.

Documented Serious Safety Considerations

Regulatory safety information highlights rare but serious reactions, including Rhabdomyolysis and potentially fatal cases of Hepatitis or Jaundice. Severe allergic reactions, such as Angioedema, are also explicitly documented.

Population-Specific Notes and Restrictions

Safety constraints are placed on use in specific patient groups. The medicine is restricted from use in individuals with active liver disease or unexplained persistent elevation of serum transaminases. It is also restricted for patients with severe renal impairment (kidney issues). Increased systemic exposure is documented in Asian patients, which may require consideration for initial assessment. Furthermore, Proteinuria (protein in urine) is a reported reaction that is typically transient and dose-dependent.

Overdose and Emergency Response

The official regulatory profile for Superstat (Rosuvastatin) overdose centers on the management of severe, dose-related toxicities. There is no specific treatment or antidote documented in the official prescribing information; therefore, treatment for overdose must be symptomatic and supportive. Hemodialysis is not expected to be beneficial due to the drug’s high plasma protein binding.

Documented Severe Manifestations

The most critical concerns related to overexposure involve the musculoskeletal and renal systems. Severe outcomes documented in regulatory labeling include Rhabdomyolysis (severe muscular breakdown) and subsequent Acute Renal Failure. Laboratory findings that warrant immediate attention include elevated Creatine Kinase (CK) levels and abnormalities in liver or renal function tests.

When Immediate Medical Help Is Required

Patients must seek immediate medical attention for unexplained and/or persistent muscular symptoms, such as muscle pain, tenderness, or weakness, particularly if these occur along with systemic signs like malaise or fever. These symptoms indicate a potential progression toward severe toxicity. The medication must be immediately discontinued if myopathy is suspected or diagnosed. In cases of severe clinical presentation, such as collapse or trouble breathing, contact with emergency services is required. Clinical monitoring following an overdose must include assessment of CK levels and renal function.

Therapeutic Uses of Superstat

What Superstat treats: main uses and benefits

Superstat is a medicine in a class generally used to address symptoms related to systemic imbalance, specifically high blood lipid levels, such as low-density lipoprotein (LDL) cholesterol—often referred to as “bad” cholesterol. This drug is relevant for easing this systemic imbalance by helping manage the high levels of certain lipids.

The core therapeutic domain is commonly used to help with lowering this lipid level and managing conditions associated with acute or disruptive episodes, such as Cardiovascular Disease (CVD). These are examples of conditions involving episodic or fluctuating manifestations.

In clinical scenarios, the medication may assist with maintaining functional stability by managing the underlying risk factors. This approach supports the patient and is considered relevant for easing the overall symptom burden associated with conditions where symptoms may intensify temporarily. As a patient-oriented benefit, it contributes to improved comfort during symptomatic periods.

“The supportive relief helps ease day-to-day comfort during symptomatic periods, supporting patients during episodes of heightened discomfort.”

Quick Fact: Relevant for managing symptoms that interfere with daily comfort

Eligibility and Restrictions for Use

The eligibility for Superstat is strictly defined by regulatory authorities based on physiological status, organ function, and age. The medicine is classified as an HMG-CoA reductase inhibitor, and its use is subject to the following official eligibility rules:

Contraindicated Populations

Superstat must not be used by the following groups, as stated in regulatory labels:

  • Pregnancy and Lactation: Women who are pregnant, may become pregnant, or are nursing mothers.
  • Active Organ Disease: Patients with active liver disease, including unexplained, persistent elevations in hepatic transaminase levels.
  • Hypersensitivity: Individuals with a known hypersensitivity to rosuvastatin or any component of the formulation.
  • Muscle Conditions: Patients with pre-existing myopathy or those receiving concomitant treatment with Ciclosporin.

Conditional and Age-Related Eligibility

  • Renal Impairment: Use is restricted. The drug is often contraindicated in severe renal impairment (Creatinine Clearance <30 mL/min) by some authorities, while others limit the maximum daily dose for this population.
  • Muscle Risk Factors: Use is restricted in patients with predisposing factors for muscle toxicity, such as hypothyroidism or a history of hereditary muscular disorders.
  • Age: Approved for use in adults. For pediatric patients (children and adolescents), use is restricted to those above a minimum, established age (typically 6 to 8 years) for specific forms of familial hypercholesterolemia. Use in children younger than 6 years is generally not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Superstat (Rosuvastatin calcium) describes interactions primarily based on two key mechanisms: altering drug exposure and increasing the risk of adverse muscle effects.

Pharmacokinetic Interactions and Restrictions

Interactions that significantly change Superstat's concentration in the body are largely mediated by specific drug transporters, notably OATP1B1 and BCRP, which manage the drug's uptake and efflux. Co-administering Superstat with inhibitors of these transporters, such as Cyclosporine or certain Anti-HIV/Anti-HCV medications, results in substantially increased systemic exposure.

Classification Interacting Agents Official Restriction/Outcome
Exposure Increase (Severe) Sofosbuvir/velpatasvir/voxilaprevir, Ledipasvir/sofosbuvir Concomitant use is not recommended
Exposure Increase (Risk) Gemfibrozil, Atazanavir/Ritonavir, Regorafenib Use with caution or avoid co-administration
Exposure Decrease Aluminum and Magnesium Hydroxide Antacids Requires timing separation

Pharmacodynamic and Timing Constraints

Interactions with other drugs may create an additive pharmacodynamic risk. Combining Superstat with other Fibrates or high-dose Niacin (ge 1 g/day) is associated with an increased risk of adverse skeletal muscle effects. The concurrent use of Coumarin Anticoagulants (e.g., Warfarin) is documented to prolong the International Normalized Ratio (INR), necessitating close regulatory monitoring. Additionally, Superstat must be taken at least two hours after antacids containing aluminum and magnesium hydroxide to prevent a marked reduction in its absorption. In certain populations, such as Asian patients, a higher baseline systemic exposure of rosuvastatin has been officially noted, which may influence overall interaction sensitivity.

Mechanism of Action

How Superstat Works

Selective Inhibition of Cholesterol Biosynthesis

Superstat acts as a selective competitive inhibitor of the enzyme HMG-CoA reductase within hepatocytes . This enzyme is the rate-limiting step of the cholesterol biosynthesis pathway. Selective blockade reduces the cellular synthesis of cholesterol, triggering a homeostatic response that underlies the subsequent lipid modulation cascade.


Cascade of Enhanced Systemic Lipid Clearance

The reduction in intracellular cholesterol levels activates the SREBP transcription factor, which leads to the marked upregulation of LDL receptors on the liver cell surface. This enhanced capacity for receptor-mediated endocytosis accelerates the removal of circulating LDL-C from the bloodstream, resulting in a decreased concentration in plasma.


Pleiotropic Modulation of Vascular Pathways

Beyond the primary lipid mechanism, the drug modulates intracellular signaling. Inhibition of HMG-CoA reductase reduces the production of non-sterol isoprenoids, which are necessary for the function of small cellular signaling proteins like Rho GTPases. This downstream effect influences the factors contributing to endothelial function and local inflammatory signaling, contributing to the resulting physiological changes.

Dosage and Administration Information

How to Use Superstat

Superstat (rosuvastatin calcium) is administered exclusively by the oral route as a film-coated tablet, a standard practice for this class of medicine. The dosing schedule is defined as once daily and the medication may be taken at any time of day, with or without food, supporting consistency in daily routine. The tablet should be swallowed whole.


Dosing Regimens and Adjustments

Adult dosing typically falls within a range of 5 mg to 40 mg once daily. The usual starting dose for most adult patients is 10 mg or 20 mg. The maximum dose of 40 mg is reserved for specific patient scenarios who have not reached their lipid goals on the 20 mg dose. Dose adjustments, or titrations, should be considered only at intervals of 4 weeks or more following initiation or a previous change in dosage, after lipid levels have been analyzed.


Administration in Specific Populations

Official labeling mandates specific dose considerations for certain groups to account for systemic exposure:

  • Asian Patients: Treatment should be initiated at 5 mg once daily.
  • Severe Renal Impairment: The starting dosage is 5 mg once daily and should not exceed 10 mg once daily for patients not undergoing hemodialysis.
  • Antacid Timing: If taking an antacid containing aluminum and magnesium hydroxide, Superstat must be administered at least 2 hours before or 4 hours after the antacid to maintain absorption.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Superstat

This section provides an overview of the types of research conducted on Superstat, describing the study populations and the outcomes that were measured.


Evidence for Managing High Blood Lipids (Dyslipidemia)

Research has focused on studying the patterns observed when Superstat is administered in trials examining changes in the body's lipid profile. This involved numerous short-term randomized controlled trials (RCTs) where the medication was studied for examining changes in blood markers like Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides. These studies typically involved adults diagnosed with high cholesterol.

Findings describe patterns of change in these key lipid biomarker measurements over defined time intervals. Research also monitored changes in the levels of High-Density Lipoprotein Cholesterol (HDL-C).


Evidence for Preventing Cardiovascular Events

Superstat research examined event rates related to outcomes reflecting episodic or acute changes in the heart and blood vessels. This research involved large-scale, long-term RCTs that monitored thousands of adults over periods of several years. Trials evaluated participants in two main groups: patients with established heart disease and patients without heart disease but with multiple risk factors.

The studies monitored the occurrence of outcomes reflecting episodic or acute changes, such as heart attack and stroke, often grouped as Major Adverse Cardiovascular Events (MACE). For patients with risk factors but no prior disease, research described patterns related to event rates that varied between the Superstat and placebo arms.


Studies in Specific Patient Populations and Uncertainties

Specific research has explored the use of Superstat in certain populations. Research examined sub-cohorts of major cardiovascular event trials, where participants were aged 70 or older. Studies were also conducted for children and teenagers (10 to 17 years old) diagnosed with inherited high cholesterol conditions.

While there is a large volume of evidence, comparative evidence is lacking from dedicated, long-term RCTs that directly measure cardiovascular event rates between Superstat and all other statins. Additionally, data for certain groups remain insufficient, and for long-term questions involving specific, narrow patient groups, certainty remains low.

Key Studies & References Rosuvastatin: a clinical review of its cardiovascular risk reduction and safety

Frequently Asked Questions (FAQ)

Common questions about Superstat (FAQ)


Q: What is the main difference between Superstat and other statin-like medicines?

Official information describes Superstat (rosuvastatin) as a high-potency medicine that selectively and competitively works to block the HMG-CoA reductase enzyme. It is described as a fully synthetic compound, and regulatory documents note certain differences in how it is processed by the body compared to some older compounds in its class.


Q: Is Superstat used for anything other than high cholesterol?

According to official regulatory indications, the medicine is prescribed not only for lowering high cholesterol (dyslipidemia) but also for reducing the risk of major cardiovascular events. This includes outcomes such as heart attack and stroke in specific patient populations.


Q: How does Superstat affect the liver?

Superstat's primary site of action is the liver, where it works to reduce cholesterol synthesis. Due to its primary site of action, regulatory warnings state that the medicine is contraindicated (must not be used) in patients who have active liver disease. Official safety data also reports rare instances where patients may experience elevations in liver enzymes.


Q: Can Superstat be taken with common pain relievers like ibuprofen or Tylenol?

The official product label details potential interactions primarily with strong drug transporter inhibitors and other lipid-lowering agents. However, common, over-the-counter pain relievers such as ibuprofen (an NSAID) or acetaminophen are not specifically listed in the regulatory documentation as interacting agents that require a dose change or contraindication.


Q: Can people with kidney problems still use Superstat?

Use of Superstat by people with kidney problems is conditional and depends on the severity of the impairment. Regulatory guidelines specify that for patients with severe kidney problems (renal impairment), the starting dose is required to be a lower dose, and the maximum daily dose is restricted.


Q: Can Superstat be taken with common stomach acid reducers?

Official drug interaction information addresses certain stomach acid reducers. If the acid reducer contains aluminum and magnesium hydroxide, Superstat administration is required to be separated by at least 2 hours before or 4 hours after the antacid. This timing separation is noted to prevent the antacid from reducing the absorption of Superstat.


Q: Does Superstat have any effect on blood sugar levels?

Official safety data confirms that Superstat can impact blood sugar regulation. New-onset Diabetes Mellitus (the development of new diabetes) is officially documented as a common adverse reaction in patients treated with the medicine.


Q: Can I take Superstat if I have a history of thyroid problems?

Official regulatory warnings list untreated hypothyroidism (an underactive thyroid condition) as a predisposing factor for muscle toxicity. This is a factor that requires clinical consideration when evaluating the risk profile for the medicine.


Q: Is Superstat used to lower triglycerides as well as cholesterol?

Yes, official regulatory indications confirm the medicine is used to treat elevated levels of multiple fats in the blood. Superstat is indicated as an adjunct to diet for reducing elevated levels of triglycerides in addition to reducing elevated total and LDL cholesterol.


Q: Can Superstat cause digestive issues like diarrhea or constipation?

Official safety data lists constipation and abdominal pain as common side effects observed in clinical trials. While not listed as common, official post-marketing reports indicate that diarrhea is sometimes reported as a less common side effect.


Q: How quickly should someone start to notice an effect after taking Superstat?

According to official pharmacodynamics data, the therapeutic response to the medicine is usually evident within one week of starting treatment. About 90% of the maximum effect on cholesterol levels is typically reached within two weeks.


Q: Do I need to change my diet while taking Superstat?

Superstat is officially indicated as an adjunct to diet. Regulatory labeling specifies the need for a standard cholesterol-lowering diet before starting the medicine. This standard cholesterol-lowering diet is intended to be maintained during the course of treatment.


Q: What types of food should I be careful about when using Superstat?

The official product label does not list any common foods that require special caution while using Superstat. It is important to note that unlike some other statin medicines, rosuvastatin (the active ingredient in Superstat) is not known to interact with grapefruit or grapefruit juice.


Q: Is there a maximum age for taking Superstat?

There is no official maximum age restriction explicitly stated in regulatory documentation. Clinical trials included patients who were 70 years and older, and close monitoring in the elderly population is generally noted in regulatory documents.


Q: What happens if I miss taking Superstat for one day?

Official patient information generally describes the procedure for a missed dose as skipping the dose and taking the next one at the scheduled time. It specifies that patients should not take a double dose to make up for a missed one.


Q: Does Superstat have any known long-term side effects?

Clinical trials covering long-term use have established the safety profile listed in regulatory documents. Long-term risks include the rare potential for serious events like Rhabdomyolysis and certain liver issues, as well as the common risk of new-onset Diabetes Mellitus.


Q: Can taking Superstat affect fertility in men or women?

Official regulatory documents do not contain clinical data suggesting that Superstat affects human male or female fertility. However, the medicine is formally restricted from use during pregnancy and lactation.


Q: Does Superstat interact with alcohol?

Regulatory documents list the consumption of substantial quantities of alcohol as a predisposing factor for muscle toxicity and liver risk. This factor requires specific clinical consideration when the medicine is prescribed.


Q: What kind of regular blood tests are usually needed while taking Superstat?

Official regulatory warnings describe the need for tests of Liver Function (transaminase levels) and monitoring of Creatine Kinase (CK) levels for patients with predisposing factors for muscle toxicity.


Q: How is the effectiveness of Superstat typically measured by doctors?

The effectiveness of the medicine is generally measured by tracking the reduction in circulating lipid levels, specifically Low-Density Lipoprotein Cholesterol (LDL-C). These measurements are used to determine if the therapeutic goals for the patient have been achieved.


Q: Are there any herbal supplements or vitamins that interact with Superstat?

The official label mainly focuses on interactions with other prescription drugs. However, it specifically warns against co-administration with other lipid-lowering therapies, such as high-dose niacin (ge 1 g/day), to avoid increasing the risk of muscle problems.


Q: Why do doctors often prescribe Superstat to patients who haven't had a heart event?

Superstat is officially indicated to reduce the risk of major cardiovascular events (like heart attack or stroke) in adults who do not have established heart disease. This use is based on research involving patients who have multiple cardiovascular risk factors.


Q: Is it okay to drive or operate machinery while taking Superstat?

Official patient information generally states that the medicine has no or negligible influence on the ability to drive or use machines. However, patients are advised to be aware of possible side effects, such as dizziness, that could potentially impact these activities.


Q: Do certain ethnic groups respond differently to Superstat?

Official regulatory labeling notes that patients of Asian descent have an approximately two-fold increased systemic exposure to Superstat. This difference in how the body handles the drug has led to a regulatory specification for a lower initial starting dose for this population.


Q: Is it normal to feel slightly fatigued when starting Superstat?

Official safety data lists Asthenia (a general lack of energy or weakness) as a common side effect. This condition may be perceived by a patient as fatigue when starting the medicine.


Q: How long does the effect of Superstat last after a dose?

Pharmacokinetic data from regulatory documents show that the elimination half-life of Superstat is approximately 19 hours. This duration of action is what supports the administration of the medicine once daily.


Q: Is Superstat an anticoagulant (blood thinner)?

No, Superstat is classified as an HMG-CoA reductase inhibitor, a class of medicine also known as a statin, and its primary action is to lower cholesterol. While it is not a blood thinner itself, regulatory documents warn that it does interact with Coumarin anticoagulants (like Warfarin), requiring careful monitoring.


Q: What happens in the body if you suddenly stop taking Superstat?

Stopping therapy can cause cholesterol levels to return to pre-treatment levels over time. Official documentation suggests that discontinuation of statin therapy may be associated with an increased risk of a major cardiovascular event.


Q: Are there any reported interactions between Superstat and grapefruit juice?

No, official patient information confirms that rosuvastatin (the active ingredient in Superstat) is not known to interact with grapefruit or grapefruit juice. This is a distinction from certain other medicines in the statin class.


Q: Why do some people report joint pain when using Superstat?

The official label lists myalgia (muscle pain) as a common side effect observed in trials. While not consistently categorized by frequency, joint pain (arthralgia) has also been reported in post-marketing and other safety data.


Q: What does the term 'Superstat monotherapy' refer to?

Regulatory documents use the term monotherapy to refer to the use of Superstat as the sole prescribed agent for lowering cholesterol. This means the patient is not taking other major lipid-lowering drugs alongside it for that purpose.


Q: Why is Superstat sometimes prescribed alongside other heart medicines?

Superstat is indicated to reduce cholesterol, which is a key component of cardiovascular risk reduction. It is often prescribed as part of a regimen with other cardiac medicines, and the regulatory label specifies that it does not have major interactions with certain common heart agents like digoxin.


Q: Is it required to take Superstat at the exact same time every day?

Official administration instructions specify that the medicine be taken once daily. Due to its long half-life of approximately 19 hours, it can be taken at any time of day, with or without food. Consistent daily administration is primarily recommended for better patient adherence.

How should Superstat be stored and disposed of?

How to Store and Dispose of Superstat (Rosuvastatin Calcium)

Storage and disposal requirements for Superstat film-coated tablets are defined by regulatory labeling to ensure product integrity and safety.

Storage Conditions Requirement
Temperature Range Store at controlled room temperature, 20 C to 25 C (68 F to 77 F). Excursions up to 30 C are permitted.
Container Rule The medicine must be kept in its original container as supplied.
Child Safety Mandatorily keep the product out of the sight and reach of children.

For disposal, unused or expired Superstat tablets must not be discarded in standard household waste or flushed down the toilet. Disposal must strictly follow local requirements, typically by utilizing drug take-back programs or authorized collection points for medicinal waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Superstat found in:

A-Z Index: